Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies

Active Cooperative Agreement Awarded Last action

Award ID
U01CA271407
Recipient
Awarding agency
Obligated
$5,551,903

Award facts

Assistance listing
93.394 Cancer Detection and Diagnosis Research
Completion date 89% complete
Place of performance
Seattle, WA 98109, USA

Award details come from USAspending.gov.

Description

Abstract
Melanoma is the deadliest form of skin cancer. Its incidence is on the rise with 106,000 new cases expected in the U.S. In 2021. Immune checkpoint inhibitors (ICIS) have revolutionized the treatment of early and advanced melanoma, with concurrent anti-ctla-4 and anti-PD-1 monoclonal antibodies demonstrating a response in ~50% of patients, including highly durable responses. Unfortunately, there are no adequate biomarkers to predict response to single agent or combination ICI, and dual checkpoint blockade is associated with significant grade 3/4 immune-related adverse events (IRAES) in ~55% of patients. The goals of our ptrc are designed to address two unmet clinical needs: (I) improve our understanding of mechanisms of resistance to ICIS to design more effective immunotherapies and combinations, and (II) identify potential biomarkers to select patients appropriately for single agent VS combination immunotherapies and to predict and monitor IRAES. In our preclinical arm, we will perform integrated proteogenomic analysis of clinically annotated, pre-treatment biopsies from melanoma patients who received ICI. The data will be analyzed in the context of clinical annotations to refine an existing signature of melanoma ICI response identified by our team and to further elucidate mechanisms of ICI response/resistance and signatures associated with IRAES. In our clinical arm, we will analyze clinical trial biospecimens using MRM-based assays to confirm & extend findings generated in the preclinical arm.

Transactions

Action Obligated Date
Amendment $829,054
Amendment $0
Amendment $0
Amendment $119,054
Amendment $1,071,493
Amendment $0
Amendment $0
Amendment $1,122,409
Amendment $0
Amendment $0
Amendment $1,156,887
Amendment $0
Original award $1,253,006
Show all 13

Subawards

Subrecipient Amount Awarded
Mount Sinai Hospital Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of early and advanced melanoma, with concurrent anti-CTLA-4 and anti-PD-1 monoclonal… $103,790
New York University Dr. Ata Moshiri will collaborate on the proteogenomic approaches to elucidating mechanisms of response/resistance to immune checkpoint inhibition in melanoma.… $38,195
Weill Medical College Of Cornell University Dr. Wolchok will be a co-investigator on this proposal entitled, “Proteogenomic studies to understand mechanisms and drivers of resistance to… $10,319
University Of Washington The University of Washington, under the Direction of Dr. Hoofnagle will provide my expertise in clinical chemistry laboratory testing to immune checkpoint… $17,711
Weill Medical College Of Cornell University Dr. Wolchok will be a co-investigator on this proposal entitled, “Proteogenomic studies to understand mechanisms and drivers of resistance to… $37,668
University Of Pittsburgh - Of The Commonwealth System Of Higher Education In the Pre-Clinical Arm, Dr. Davar will assist Dr. Paulovich’s team in analyzing clinically annotated, pre-treatment tissue biopsies from melanoma patients… $83,380
Icahn School Of Medicine At Mount Sinai Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of early and advanced melanoma, with concurrent anti-CTLA-4 and anti-PD-1 monoclonal… $92,730
University Of Washington The University of Washington, under the Direction of Dr. Hoofnagle will provide my expertise in clinical chemistry laboratory testing to immune checkpoint… $17,239
New York University Dr. Ata Moshiri will collaborate on the proteogenomic approaches to elucidating mechanisms of response/resistance to immune checkpoint inhibition in melanoma.… $8,490
New York University Dr. Ata Moshiri will collaborate on the proteogenomic approaches to elucidating mechanisms of response/resistance to immune checkpoint inhibition in melanoma.… $8,490
University Of Pittsburgh - Of The Commonwealth System Of Higher Education In the Pre-Clinical Arm, Dr. Davar will assist Dr. Paulovich’s team in analyzing clinically annotated, pre-treatment tissue biopsies from melanoma… $75,147
University Of Washington The University of Washington, under the Direction of Dr. Hoofnagle will provide my expertise in clinical chemistry laboratory testing to immune checkpoint… $14,026
Icahn School Of Medicine At Mount Sinai Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of early and advanced melanoma, with concurrent anti-CTLA-4 and anti-PD-1 monoclonal… $69,998
New York University Performance Site: New York University Grossman School of Medicine (NYUGSOM) Dr. Ata Moshiri will collaborate on the proteogenomic approaches to elucidating… $42,968
Show all 14

Quick answers

Who received award U01CA271407?

U01CA271407 was awarded to Fred Hutchinson Cancer Center by National Cancer Institute (National Institutes of Health) on June 16, 2022.

How much is award U01CA271407 worth?

$5,551,903 has been obligated on U01CA271407.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award